|
Volume
18 Number 2
29 February 2016
|
|
Home
>
Publications
>
Current
Neuro-Oncology >
Volume
18, Year 2016 >
Number 2, 29 February
|
|
|
|
|
|
Chakraborty
S, Priamo F, Boockvar JA.
Magnetic
Resonance Imaging to Identify Glioblastoma Molecular
Phenotypes.
Neurosurgery.
2016 Feb 1;78(2):N20-1→.
doi: 10.1227/01.neu.0000479895.10242.9d→.
PMID: 26779797→
Comment.
ˍ
Refers
to:
Itakura H, et al., Magnetic resonance image features identify
glioblastoma phenotypic subtypes with distinct molecular pathway
activities.
Sci
Transl Med. 2015 Sep 2;7(303):303ra138→.
doi: 10.1126/scitranslmed.aaa7582→.
PMID: 26333934→.
Observational
study. ˍ
|
|
|
*
|
Redjal
N, Reinshagen C, Le A, Walcott BP, McDonnell E, Dietrich J, Nahed
BV.
Valproic
acid, compared to other antiepileptic drugs, is associated with
improved overall and progression-free survival in glioblastoma but
worse outcome in grade II/III gliomas treated with temozolomide.
J
Neurooncol. 2016 Feb 1, 2016;127(3):505-14→.
doi: 10.1007/s11060-016-2054-8→.
PMID: 26830093→.
Observational
study. ˍ
|
|
|
|
Zussman
BM, Engh JA.
Patterns
of Care and Clinical Decision Making for Recurrent Glioblastoma
Multiforme.
Neurosurgery.
2016
Feb 1;78(2):N12-4→.
doi: 10.1227/01.neu.0000479889.72124.20→.
PMID: 26779791→.
Comment.
ˍ
Refers
to: Hundsberger
T, et al., Patterns of care in recurrent glioblastoma in
Switzerland: a multicentre national approach based on diagnostic
nodes.
J
Neurooncol. 2015
Oct 12, 2016;126(1):175-183→.
doi: 10.1007/s11060-015-1957-0→.
PMID: 26459327→.
Interventional study.
ˍˍˍ
|
|
|
|
Romero
D.
Genetics:
Divergence shapes recurrence.
Nat
Rev Clin Oncol.
2016 Feb 2, 2016;13(3):136→.
doi: 10.1038/nrclinonc.2016.14→.
PMID:
26831182→.
Comment. ˍ
Refers
to: Morrissy
AS, et al., Divergent clonal selection dominates medulloblastoma
at recurrence.
Nature.
2016 Jan 13, 2016;529(7586):351-7→.
doi: 10.1038/nature16478→.
PMID:
26760213→.
Laboratory investigation. ˍ
|
|
|
|
Wheeler
LA, Manzanera AG, Bell SD, Cavaliere R, McGregor JM, Grecula JC,
Newton HB, Lo SS, Badie B, Portnow J, Teh BS, Trask TW, Baskin DS,
New PZ, Aguilar LK, Aguilar-Cordova E, Chiocca EA.
Phase
2 multicenter study of gene-mediated cytotoxic immunotherapy as
adjuvant to surgical resection for newly diagnosed malignant
glioma.
Neuro
Oncol. 2016 Feb 2, 2016;18(8):1137-45→.
doi: 10.1093/neuonc/now002→.
PMID: 26843484→.
Interventional study. ˍ
|
|
|
|
Balana
C, De Las Penas R, Sepúlveda JM, Gil-Gil MJ, Luque R,
Gallego O, Carrato C, Sanz C, Reynes G, Herrero A, Ramirez JL,
Pérez-Segura P, Berrocal A, Vieitez JM, Garcia A,
Vazquez-Estevez S, Peralta S, Fernandez I, Henriquez I,
Martinez-Garcia M, De la Cruz JJ, Capellades J, Giner P, Villà
S.
Bevacizumab
and temozolomide versus temozolomide alone as neoadjuvant
treatment in unresected glioblastoma: the GENOM 009 randomized
phase II trial.
J
Neurooncol. 2016 Feb 3, 2016;127(3):569-79→.
doi: 10.1007/s11060-016-2065-5→.
PMID: 26847813→.
Interventional
study. ˍ
|
|
|
|
Jungk
C, Chatziaslanidou D, Ahmadi R, Capper D, Bermejo JL, Exner J, von
Deimling A, Herold-Mende C, Unterberg A.
Chemotherapy
with BCNU in recurrent glioma: Analysis of clinical outcome and
side effects in chemotherapy-naïve patients.
BMC
Cancer. 2016 Feb 10;16:81→.
doi: 10.1186/s12885-016-2131-6→.
PMID: 26865253→.
Observational
study. ˍ
|
|
|
|
Vogelbaum
MA.
The
benefit of surgical resection in recurrent glioblastoma.
Neuro
Oncol. 2016 Feb 10, 2016;18(4):462-3→.
doi: 10.1093/neuonc/now004→.
PMID: 26869588→.
Editorial.
ˍ
Refers
to: Suchorska
B, et al., Complete resection of contrast-enhancing tumor volume
is associated with improved survival in recurrent
glioblastoma-results from the DIRECTOR trial.
Neuro Oncol.
2016 Jan 27, 2015;18(4):549-56→.
doi: 10.1093/neuonc/nov326→.
PMID: 26823503→.
Interventional study. ˍ
|
|
|
|
Brandes
AA, Bartolotti M, Tosoni A, Poggi R, Bartolini S, Paccapelo A,
Bacci A, Ghimenton C, Pession A, Bortolotti C, Zucchelli M, Galzio
R, Talacchi A, Volpin L, Marucci G, de Biase D, Pizzolitto S,
Danieli D, Ermani M, Franceschi E.
Patient
outcomes following second surgery for recurrent
glioblastoma.
Future
Oncol. 2016 Feb 16;12(8):1039-44→.
doi: 10.2217/fon.16.9→.
PMID: 26880307→.
Observational
study. ˍ
|
|
|
|
Kruser
TJ, Mehta MP, Kozak KR.
Identification
of Patients Who Benefit From Bevacizumab in High-Grade Glioma-An
Easy Question Turned Difficult: Treat the Scan or the Patient?
J
Clin Oncol. 2016 Feb 16, 2016;34(11):1281-2→.
doi: 10.1200/JCO.2015.64.7883→.
PMID: 26884565→.
Comment.
ˍ
Refers
to: Taphoorn
MJ, et al., Health-Related Quality of Life in a Randomized Phase
III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly
Diagnosed Glioblastoma.
J Clin Oncol. 2015 May 26,
2015;33(19):2166-75→.
doi: 10.1200/JCO.2014.60.3217→.
PMID: 26014298→.
Interventional study. ˍ
|
|
|
|
Vivekanandan
S, Breene R, Ramanujachar R, Traunecker H, Pizer B, Gaze MN, Saran
F, Thorp N, English M, Wheeler K, Michalski A, Walker DA, Saunders
D, Cowie F, Cameron A, Picton S, Parashar D, Horan G, Williams MV.
Reply
to Comment on: The UK Experience of a Treatment Strategy for
Pediatric Metastatic Medulloblastoma Comprising Intensive
Induction Chemotherapy, Hyperfractionated Accelerated
Radiotherapy, and Response-Directed High-Dose Myeloablative
Chemotherapy or Maintenance Chemotherapy (Milan Strategy).
Pediatr
Blood Cancer. 2016 Feb 17, 2016;63(6):1125-6→.
doi: 10.1002/pbc.25946→.
PMID: 26891280→.
Letter
to the Editor. ˍ
Refers
to:
Massimino
M, et al., Comment on: The UK Experience of a Treatment Strategy
for Pediatric Metastatic Medulloblastoma Comprising Intensive
Induction Chemotherapy, Hyperfractionated Accelerated
Radiotherapy, and Response Directed High-Dose Myeloablative
Chemotherapy or Maintenance Chemotherapy (Milan Strategy).
Pediatr
Blood Cancer.
2016 Jan 14→.
2016;63(6):1123-4. doi: 10.1002/pbc.25901→.
PMID: 26766787→.
Letter
to the Editor. ˍ
In
turn referring to:
Vivekanandan
S, et al., The UK Experience of a Treatment Strategy for Pediatric
Metastatic Medulloblastoma Comprising Intensive Induction
Chemotherapy, Hyperfractionated Accelerated Radiotherapy and
Response Directed High Dose Myeloablative Chemotherapy or
Maintenance Chemotherapy (Milan Strategy).
Pediatr
Blood Cancer.
2015 Aug 14, 2015;62(12):2132-9→.
doi: 10.1002/pbc.25663→.
PMID: 26274622→.
Observational study. ˍ
|
|
|
|
Purow
B.
For
glioma, a sweet side to diabetes.
Neuro
Oncol. 2016 Feb 19, 2015;18(3):306-7→.
doi: 10.1093/neuonc/nov328→.
PMID: 26917588→.
Editorial.
ˍ
Refers
to: Seliger
C, et al., Diabetes, use of antidiabetic drugs, and the risk of
glioma.
Neuro Oncol. 2015 Jun 20, 2015;18(3):340-9→.
doi: 10.1093/neuonc/nov100→.
PMID: 26093337→.
Observational study. ˍ
|
|
|
|
Brandes
AA, Carpentier AF, Kesari S, Sepulveda-Sanchez JM, Wheeler HR,
Chinot O, Cher L, Steinbach JP, Capper D, Specenier P, Rodon J,
Cleverly A, Smith C, Gueorguieva I, Miles C, Guba SC, Desaiah D,
Lahn MM, Wick W.
A
phase II randomized study of galunisertib monotherapy or
galunisertib plus lomustine compared with lomustine monotherapy in
patients with recurrent glioblastoma.
Neuro
Oncol. 2016 Feb 21, 2016;18(8):1146-56→.
doi:
10.1093/neuonc/now009→.
PMID:
26902851→.
Interventional
study. ˍ
|
|
|
|
Steffens
R, Semrau S, Lahmer G, Putz F, Lettmaier S, Eyüpoglu I,
Buchfelder M, Fietkau R.
Recurrent
glioblastoma: who receives tumor specific treatment and how
often?
J
Neurooncol. 2016 Feb 23, 2016;128(1):85-92→.
doi: 10.1007/s11060-016-2079-z→.
PMID: 26907492→.
Observational
study. ˍ
|
|
|
|
Cernelc
J.
Glioblastoma
with a PNET component - Report of an emerging variant with
therapeutic and prognostic implications.
Pathology.
2016 Feb 1, 2016;48 Suppl 1:S66→.
doi: 10.1016/j.pathol.2015.12.166→.
Case report
(Meeting
abstract). ˍ
|
|
|
|
|
|
|
|
|
